Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inspire Medical Systems (INSP) EBITDA Margin (2017 - 2025)

Inspire Medical Systems' EBITDA Margin history spans 9 years, with the latest figure at 50.51% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 3630.0% year-over-year to 50.51%; the TTM value through Dec 2025 reached 15.94%, up 931.0%, while the annual FY2025 figure was 15.94%, 931.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 50.51% at Inspire Medical Systems, up from 4.53% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 50.51% in Q4 2025 and bottomed at 40.24% in Q1 2021.
  • The 5-year median for EBITDA Margin is 4.36% (2021), against an average of 3.9%.
  • The largest annual shift saw EBITDA Margin skyrocketed 16592bps in 2021 before it tumbled -645bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 3.11% in 2021, then soared by 180bps to 2.49% in 2022, then skyrocketed by 224bps to 8.06% in 2023, then soared by 76bps to 14.21% in 2024, then skyrocketed by 256bps to 50.51% in 2025.
  • Per Business Quant, the three most recent readings for INSP's EBITDA Margin are 50.51% (Q4 2025), 4.53% (Q3 2025), and 1.58% (Q2 2025).